| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
Mebeverine alcohol primarily targets smooth muscle cells in the gastrointestinal tract, though as a metabolite its direct pharmacological target is less defined compared to the parent drug. The parent compound Mebeverine acts on muscarinic receptors and voltage-gated sodium channels to suppress action potential amplitude and prolong the time between stimulation and peak response. As a metabolite, Mebeverine alcohol is mainly used as a pharmacokinetic marker rather than a direct receptor-binding agent. It may also interact with esterases and glucuronidases involved in its further metabolism and conjugation.
|
|---|---|
| ln Vitro |
In vitro studies of Mebeverine alcohol primarily focus on its formation and stability in biological matrices rather than direct pharmacological activity. The compound is typically analyzed using chromatographic methods such as GC-MS to determine its concentration in plasma samples. In vitro stability assays demonstrate that Mebeverine alcohol is susceptible to glucuronidation, forming glucuronide conjugates that are cleaved by beta-glucuronidase prior to analysis. Its in vitro profile is characterized by linearity over a concentration range of 2-200 ng/mL in human plasma.
|
| ln Vivo |
In vivo, Mebeverine alcohol is the major circulating metabolite following oral administration of Mebeverine. Pharmacokinetic studies in human subjects have shown that it can be detected in plasma after peroral dosing, with its systemic levels reflecting the absorption and metabolism of the parent drug. The metabolite does not contribute significantly to the therapeutic effect but serves as a marker for drug exposure. Its in vivo behavior is characterized by formation from the parent compound, distribution in the systemic circulation, and elimination via renal pathways following glucuronidation.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Mebeverine alcohol typically involve incubation of the compound with liver microsomes or recombinant enzymes to study its metabolic pathways. Glucuronidation assays using UDP-glucuronosyltransferases (UGTs) are commonly performed to determine the formation rate of glucuronide conjugates. The assay protocol generally includes incubation of Mebeverine alcohol with microsomal protein and cofactors such as UDPGA at 37degC, followed by termination with organic solvent and analysis via LC-MS/MS or GC-MS. Binding affinity to plasma proteins can be assessed using equilibrium dialysis or ultrafiltration methods.
|
| Cell Assay |
In vitro cellular assays for Mebeverine alcohol are limited, as the compound is primarily a metabolite rather than an active therapeutic agent. When used in cell-based studies, typical protocols involve culturing hepatocytes or intestinal epithelial cells and exposing them to varying concentrations of Mebeverine alcohol to assess metabolic conversion, cellular uptake, or toxicity. Cells are maintained in appropriate culture media at 37degC with 5% CO2, treated with the compound for specified time points, and samples are collected for analysis of metabolite formation or cell viability using assays such as MTT or LC-MS/MS quantification.
|
| Animal Protocol |
In vivo animal studies for Mebeverine alcohol are typically conducted as part of the pharmacokinetic profiling of the parent drug Mebeverine. Rodent models (rats or mice) are administered Mebeverine orally or intravenously, and blood samples are collected at various time points post-dose. Plasma is processed and analyzed for Mebeverine alcohol concentration using validated bioanalytical methods such as GC-MS with selected-ion monitoring. The resulting concentration-time data are used to calculate pharmacokinetic parameters including Cmax, Tmax, AUC, and half-life, providing insights into the absorption, distribution, metabolism, and excretion of the parent compound.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Mebeverine alcohol are characterized by its role as the primary circulating metabolite of Mebeverine. Following oral administration of Mebeverine, Mebeverine alcohol appears in plasma with a pharmacokinetic profile that reflects the absorption and first-pass metabolism of the parent drug. The compound undergoes glucuronidation to form conjugates that are excreted renally. In human plasma, the metabolite can be quantified over a linear range of 2-200 ng/mL with a detection limit of 0.5 ng/mL using GC-MS methodology. Its systemic exposure is dose-dependent and may serve as a surrogate marker for Mebeverine bioavailability.
|
| Toxicity/Toxicokinetics |
Toxicological data for Mebeverine alcohol are limited, as it is primarily a metabolite and not a therapeutic agent itself. The parent drug Mebeverine has a well-established safety profile with low toxicity at therapeutic doses. As a major metabolite, Mebeverine alcohol is generally considered to have low inherent toxicity, though high concentrations may potentially cause off-target effects. In preclinical studies, the metabolite is typically evaluated as part of the overall safety assessment of Mebeverine, with no specific toxicity findings attributed directly to Mebeverine alcohol. Standard toxicological endpoints include assessment of organ function, hematology, and histopathology in animal models.
|
| Additional Infomation |
Mebeverine alcohol is the major metabolite of Mebeverine, a musculotropic antispasmodic drug used to relieve gastrointestinal spasms. It is classified as a drug metabolite and is primarily used in research settings for pharmacokinetic and bioequivalence studies. The compound is not approved as a therapeutic agent itself but is important for understanding Mebeverine's metabolism and systemic exposure. Analytical methods such as GC-MS and LC-MS/MS have been developed for its quantification in biological matrices. Mebeverine alcohol is typically stored at 2-8degC for short-term use or at -20degC for long-term storage.
|
| Molecular Formula |
C16H27NO2
|
|---|---|
| Molecular Weight |
265.39108
|
| Exact Mass |
265.204
|
| CAS # |
14367-47-6
|
| Related CAS # |
Mebeverine alcohol-d5;2070015-15-3;Mebeverine-d6 hydrochloride;1329647-20-2
|
| PubChem CID |
26649
|
| Appearance |
Light yellow to yellow liquid
|
| Density |
0.994g/cm3
|
| Boiling Point |
386.4ºC at 760mmHg
|
| Flash Point |
187.5ºC
|
| Vapour Pressure |
1.16E-06mmHg at 25°C
|
| Index of Refraction |
1.512
|
| LogP |
2.72
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
19
|
| Complexity |
215
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN(CCCCO)C(C)CC1=CC=C(C=C1)OC
|
| InChi Key |
ZGZAPRVKIAFOPL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H27NO2/c1-4-17(11-5-6-12-18)14(2)13-15-7-9-16(19-3)10-8-15/h7-10,14,18H,4-6,11-13H2,1-3H3
|
| Chemical Name |
4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butan-1-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~376.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7680 mL | 18.8402 mL | 37.6804 mL | |
| 5 mM | 0.7536 mL | 3.7680 mL | 7.5361 mL | |
| 10 mM | 0.3768 mL | 1.8840 mL | 3.7680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
